MAPT and Alzheimer disease: A recent study using a novel knock‐in mouse model of AD, AppNL/NL carrying the Swedish “NL” mutation, showed that chronic HFD treatment does not trigger AD‐associated pathological alterations, such as hippocampal amyloidosis, Tau phosphorylation, and cognitive impairment, although mild impairments in both hippocampal long‐term potentiation and social memory were observed (Salas et al., 2018).